pp-190 Capsules
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Pulmonary sarcoidosis — treatment of granulomatous lung inflammation
Clinical stage: Phase 2
Modality: Small molecule (first-in-class dual enzyme inhibitor)
Mechanism / Target: First-in-class dual inhibitor of acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1); reduces chitin-driven macrophage/monocyte activation and granuloma formation in sarcoidosis
Route / form: Oral capsule
Differentiation: First-in-class dual chitinase inhibitor; novel immune-metabolic target in pulmonary sarcoidosis; no approved targeted pharmacotherapy for sarcoidosis;
Manufacturer #39330
Europe-based clinical-stage biotech developing Rx small-molecule drugs against novel RNA and protein targets for serious diseases. Pipeline spans oncology and fibrotic/inflammatory conditions. Conducts global clinical development with partners across Europe and North America.
None